[go: up one dir, main page]

PE20030334A1 - ANTICUERPOS HUMANOS ANTAGONISTAS ANTI-hTNFSF13b - Google Patents

ANTICUERPOS HUMANOS ANTAGONISTAS ANTI-hTNFSF13b

Info

Publication number
PE20030334A1
PE20030334A1 PE2002000745A PE2002000745A PE20030334A1 PE 20030334 A1 PE20030334 A1 PE 20030334A1 PE 2002000745 A PE2002000745 A PE 2002000745A PE 2002000745 A PE2002000745 A PE 2002000745A PE 20030334 A1 PE20030334 A1 PE 20030334A1
Authority
PE
Peru
Prior art keywords
hcvr
lcvr
inflammatory disease
htnfsf13b
cdr3
Prior art date
Application number
PE2002000745A
Other languages
English (en)
Inventor
Valentina Pavlovna Gelfanova
Derrick Ryan Witcher
Kristine Kay Kikly
John Edward Hale
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23213094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030334(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20030334A1 publication Critical patent/PE20030334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANO ANTI hTNFSF13b QUE COMPRENDE UN POLIPEPTIDO DE PREFERENCIA CDR1 DE REGION VARIABLE DE CADENA LIGERA LCVR; CDR2 DE LCVR, CDR3 DE LCVR; CDR1 DE REGION VARIABLE DE CADENA PESADA HCVR, CDR2 DE HCVR, CDR3 DE HCVR; SE CARACTERIZA POR KD DE 1*10(-8)M, CONSTANTE DE VELOCIDAD Ksep 5*10(-4)S(-1); CI50 DE 1*10(-8)M; HCVR SE SELECCIONA DE IgG1, IgG2, IgG3, IgG4 (PROLINA POR SERINA EN POSICION 231), IgA, IgE, IgM, IgD; REGION CONSTANTE DE CADENA LIGERA KAPPA, LAMBDA. EL ANTICUERPO INHIBE ACTIVIDAD DE TNFSF13b EN UN SUJETO QUE PADECE TRASTORNO INMUNE COMO LUPUS ERITEMATOSO, ARTRITIS REUMATOIDE, ARTRITIS CRONICA JUVENIL, ENFERMEDAD DE CROHN, COLITIS ULCEROSA, ENFERMEDAD INFLAMATORIA DEL INTESTINO, RECHAZO DE TRASPLANTE
PE2002000745A 2001-08-16 2002-08-16 ANTICUERPOS HUMANOS ANTAGONISTAS ANTI-hTNFSF13b PE20030334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31280801P 2001-08-16 2001-08-16

Publications (1)

Publication Number Publication Date
PE20030334A1 true PE20030334A1 (es) 2003-04-05

Family

ID=23213094

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000745A PE20030334A1 (es) 2001-08-16 2002-08-16 ANTICUERPOS HUMANOS ANTAGONISTAS ANTI-hTNFSF13b

Country Status (26)

Country Link
US (4) US7317089B2 (es)
EP (2) EP2348048B1 (es)
JP (1) JP4012880B2 (es)
KR (1) KR100961299B1 (es)
CN (1) CN100497392C (es)
AR (1) AR035119A1 (es)
AU (2) AU2002322436C1 (es)
BR (1) BR0211630A (es)
CA (1) CA2452447C (es)
CO (1) CO5560617A2 (es)
DK (2) DK1432735T3 (es)
EA (1) EA009074B1 (es)
EC (1) ECSP044978A (es)
ES (2) ES2526990T3 (es)
HR (1) HRP20040147A2 (es)
HU (1) HU230006B1 (es)
IL (1) IL160373A0 (es)
MX (1) MXPA04001344A (es)
NO (1) NO20040603L (es)
NZ (1) NZ530657A (es)
PE (1) PE20030334A1 (es)
PL (1) PL212404B1 (es)
PT (2) PT2348048E (es)
UA (1) UA89017C2 (es)
WO (1) WO2003016468A2 (es)
ZA (1) ZA200401154B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
WO2006025345A1 (ja) * 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトｂａｆｆ抗体
CA2898009C (en) 2005-05-16 2018-03-27 Rebecca S. Hoffman Use of tnfa inhibitor for treatment of erosive polyarthritis
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007056288A2 (en) * 2005-11-08 2007-05-18 Biogen Idec Ma Inc. Methods of evaluating baff
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101541791B1 (ko) 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
US20100189723A1 (en) * 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR102094022B1 (ko) 2013-04-29 2020-03-30 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US20170101466A1 (en) * 2014-06-03 2017-04-13 Masahisa Handa Anti-blys antibodies
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN118515767B (zh) * 2024-07-23 2024-10-18 江苏双全生物医药科技有限公司 一种TNFSF13b抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
IL134480A0 (en) 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US6787638B1 (en) 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
EP1415659B9 (en) 1999-01-25 2012-02-15 Biogen Idec MA Inc. An antibody specific for soluble BAFF for use in the treatment of cancer
AU777536B2 (en) 1999-02-23 2004-10-21 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS

Also Published As

Publication number Publication date
ZA200401154B (en) 2005-06-22
HUP0500816A3 (en) 2010-01-28
BR0211630A (pt) 2004-11-09
DK1432735T3 (da) 2012-08-06
ES2526990T3 (es) 2015-01-19
NZ530657A (en) 2006-02-24
US7728109B2 (en) 2010-06-01
CA2452447C (en) 2012-04-24
US8173124B2 (en) 2012-05-08
DK2348048T3 (en) 2014-12-15
CN100497392C (zh) 2009-06-10
JP2005517384A (ja) 2005-06-16
MXPA04001344A (es) 2004-05-05
AU2002322436B9 (en) 2009-04-09
WO2003016468A2 (en) 2003-02-27
WO2003016468A3 (en) 2003-11-20
ECSP044978A (es) 2004-03-23
HU230006B1 (en) 2015-04-28
US7317089B2 (en) 2008-01-08
US20120195904A1 (en) 2012-08-02
US20100272735A1 (en) 2010-10-28
PT2348048E (pt) 2015-02-04
CN1541224A (zh) 2004-10-27
EP2348048B1 (en) 2014-11-19
HUP0500816A2 (en) 2007-07-30
AR035119A1 (es) 2004-04-14
AU2008246261A1 (en) 2008-12-11
PL212404B1 (pl) 2012-09-28
UA89017C2 (uk) 2009-12-25
KR100961299B1 (ko) 2010-06-04
KR20040030088A (ko) 2004-04-08
AU2002322436B2 (en) 2008-12-04
EP1432735A2 (en) 2004-06-30
EA200400312A1 (ru) 2004-10-28
AU2002322436C1 (en) 2011-09-01
EP1432735B1 (en) 2012-07-18
EA009074B1 (ru) 2007-10-26
AU2008246261B2 (en) 2011-04-07
IL160373A0 (en) 2004-07-25
PT1432735E (pt) 2012-09-10
CA2452447A1 (en) 2003-02-27
EP2348048A1 (en) 2011-07-27
NO20040603L (no) 2004-05-14
HRP20040147A2 (en) 2004-10-31
US20080175841A1 (en) 2008-07-24
CO5560617A2 (es) 2005-09-30
US20050070694A1 (en) 2005-03-31
PL370534A1 (en) 2005-05-30
ES2389834T3 (es) 2012-11-02
EP1432735A4 (en) 2007-06-27
JP4012880B2 (ja) 2007-11-21

Similar Documents

Publication Publication Date Title
PE20030334A1 (es) ANTICUERPOS HUMANOS ANTAGONISTAS ANTI-hTNFSF13b
PE20090689A1 (es) Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
EP2639242A3 (en) Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2022031635A5 (es)
HRP20120606T4 (hr) Protutijela protiv il-17
JP2005517384A5 (es)
JP2019518742A5 (es)
NL300911I2 (nl) sarilumab
PE20010191A1 (es) Prevencion y tratamiento de enfermedades amiloidogenicas
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
PE20120815A1 (es) Anticuerpos anti il-17f y metodos de uso de los mismos
HRP20180776T1 (hr) Antagonisti il17c za liječenje upalnih poremećaja
HRP20250602T1 (hr) Antitijela koja se vežu na sortilin i inhibiraju vezanje progranulina
EA201001467A1 (ru) Моноклональное антитело и способ его использования
PE20141434A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
BR9907743A (pt) Anticorpos contra a il-12 humana
RU2019115610A (ru) Антитела и полипептиды, направленные против cd127
WO2005094446A3 (en) Anti-myostatin antibodies
MY165625A (en) Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis
HRP20221260T1 (hr) Humanizirana i kimerna monoklonska protutijela za cd47
NZ718973A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP2012524071A5 (es)
JP2010531846A5 (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed